Bain Capital, Mitsubishi Tanabe Pharma and Japan

Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion
U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry.
Bain Is Said to Near $3 Billion Deal for Mitsubishi Pharma Unit
Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter said, adding to a dealmaking boom in Japan.
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group.
Bain Capital buys Japanese pharma for $3.3B
Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to “accelerate the development and approval of innovative medicines in the Japanese market.
Bain to acquire Mitsubishi Tanabe Pharma in $3.3 billion deal
Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous system and metabolic disease.
Bain Capital to Buy Mitsubishi Chemical’s Pharma Business for More Than $3 Billion
The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key businesses.
Mitsubishi Chemical to sell drug unit to Bain in $3.36 billion deal
Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it seeks to streamline its portfolio.
Bain Capital to buy Mitsubishi Chemical’s pharma unit for $3.3B
Investment firm Bain Capital said on Friday that it has signed an agreement to acquire Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group (OTCPK:MTLHY) for approximately 510 billion JPY (3.3 billion USD).
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation
Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") in a carve-out transaction from Mitsubishi Chemical Group Corporation.
Private Equity And Venture Capital Deal Value Nudges Down In January
Global private equity and venture capital transaction value totaled $35.28 billion in January, down slightly compared with ...
Becker's ASC3d
Why Bain Capital's $3.2B bid for Surgery Partners could 'glaringly outline' PE's impact
Brentwood, Tenn.-based Surgery Partners received a nonbinding acquisition proposal from Bain Capital Private Equity on Jan. 27, offering to buy all outstanding shares for $25.75 per share in cash.
M&A News: Bain Capital Buys 350-Year-Old Japanese Drugs Firm for $3.4 billion
Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...
Bain Capital proposes to take Surgery Partners private
Bain Capital Private Equity has proposed to acquire the remaining shares of surgical facility operator Surgery Partners it ...
Modern Healthcare12d
Bain Capital Private Equity proposes to buy out Surgery Partners
Under the nonbinding proposal, Bain Capital Private Equity would acquire the remaining shares of Surgery Partners it does not ...
Becker's Hospital Review12d
Surgery Partners considers $3.2B private equity sale: 7 things to know
Private equity firm Bain Capital plans to fully acquire Surgery Partners, one of the five largest operators of ambulatory surgery centers, for $3.2 billion.
Bain Capital drafts in former Insignia Financial boss Renato Mota to boost its takeover tilt
Bain Capital kicked off the bidding war for MLC-owner Insignia Financial and has certainly pulled out all the stops to ...